Waiting until the end of a subject’s lifespan is quite a leaden method of validating the efficacy of a longevity-based intervention. This method could take researchers generations upon generations to eventually validate an effective intervention—or—this method might not ever yield results seen by the general public. However, researchers may have devised an innovative way to solve this problem.

“If we hope to control the aging process, we need to learn how to measure the rate of aging in shorter time periods.”

Many researchers believe that measuring the rate of human aging can be done faster by using DNA methylation-based aging clocks. Methylation-based clocks are capable of determining human biological aging with impressive accuracy. Hypermethylated and demethylated regions of DNA (CpG islands near specific aging-associated genes) play key roles in turning certain genes on and off throughout the aging process. Therefore, methylation is an important biomarker of aging. While there is a short list of currently available biological aging clocks for researchers to use in studies of anti-aging therapies, the TruAge DNA methylation test is preferable in some cases, due to its accessibility, use of simple saliva samples and cost effectiveness.

“For the first time, these biomarkers of aging give scientists the opportunity to study the effects of anti-aging compounds in real-time and directly in humans.”

In a new study, researchers from TruMe Labs, National University of Singapore and Ponce de Leon Health used the TruAge DNA methylation test to validate Rejuvant®—a patent-pending anti-aging dietary supplement. The trial study yielded unprecedented results and the research paper authored by the team was published as the cover of Aging (Aging-US) Volume 13, Issue 22, entitled: “Rejuvant®, a potential life-extending compound formulation with alpha-ketoglutarate and vitamins, conferred an average 8 year reduction in biological aging, after an average of 7 months of use, in the TruAge DNA methylation test”.

Full blog - https://www.impactjournals.com/journals/blog/aging/trending-with-impact-aging-reduced-by-8-years-with-rejuvant/

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.203736

DOI - https://doi.org/10.18632/aging.203736

Full Text - https://www.aging-us.com/article/203736/text

Correspondence to: Brian K. Kennedy email: [email protected] and Yelena V. Budovskaya email: [email protected]

Keywords: aging, DNA methylation, alpha-ketoglutarate (AKG), biologic age, Rejuvant

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at http://www.Aging-US.com​​ or connect with us on:

SoundCloud - https://soundcloud.com/Aging-Us

Facebook - https://www.facebook.com/AgingUS/

Twitter - https://twitter.com/AgingJrnl

Instagram - https://www.instagram.com/agingjrnl/

YouTube - https://www.youtube.com/agingus​

LinkedIn - https://www.linkedin.com/company/aging/

Pinterest - https://www.pinterest.com/AgingUS/

Aging-US is published by Impact Journals, LLC please visit http://www.ImpactJournals.com​​ or connect with @ImpactJrnls

Media Contact

18009220957